Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial

European Heart Journal

1 April 2021
Organised by: Logo
ESC Journals PREVENTIVE CARDIOLOGY Risk Factors and Prevention VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Contributors

Nikolaus Marx
Nikolaus Marx

Author

RWTH University Hospital Aachen Aachen , Germany

ESC 365 is supported by